Local biopharmaceutical firm to conduct phase 3 trial for Enbrel

Published: 2009-10-19 06:56:00

Updated: 2009-10-19 06:56:00

Biotrion Co., an affiliated biopharmaceutical company of Futureinfonet in Korea, says it has received approval from the Korea Food and Drug Administration to conduct phase 3 clinical trial covering its biosimilar drug of the blockbuster rheumatoid arthritis and psoriasis drug Enbrel the US based ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK